Druck Icon

Eckert & Ziegler: Solid revenues and earnings in the first half year 2012

Berlin, August 14, 2012. The Eckert & Ziegler Group (ISIN DE0005659700), a specialist in isotope applications in medicine, science and industry increased its group revenues by EUR 2.1 million (+4%) in the first half year 2012 to EUR 57.9 million. EBIT resulted in EUR 10.0 million (-16%); earnings after taxes and minority interests amounted to EUR 5.4 million
(-17%) or EUR 1.03 per share (-18%). The relative decline in earnings was solely the result of a very strong start of the year 2011; based on the entire year, revenue is according to plan.

The largest share of overall earnings is made up by the Isotope Products segment. In this segment, revenues with external customers increased slightly by 2% to EUR 28.2 million. This resulted in an EBIT of EUR 9.1 million, thereby exceeding the previous year by 4%.

Also encouraging is the revenue growth of 7% to EUR 14.0 million in the Radiation Therapy segment. In this segment, the new MultiSource® cancer radiation system was responsible for a boost in revenues. Compared to the same period of the previous year, expenditures for research and development have more than doubled in the segment. As a result, EBIT decreased by 35% to EUR 0.9 million. Comprehensive statements about the Radiation Therapy segment can be found in the quarterly report of Eckert & Ziegler BEBIG s.a. (www.bebig.eu) which is released at the same time.

In the Radiopharma segment, growth experienced a slowdown. Thanks to the acquisition of Bioscan in the previous year, the segment achieved a revenue growth of 2% to EUR 12.7 million. Compared to the same period last year, expenditures in the production and sales areas increased. As a result, EBIT decreased by 37% to EUR 1.4 million. However, if the second quarter of 2012 is viewed in isolation, it reveals a positive trend: Compared to the same period of the previous year, EBIT increased during the last three months by 22% to EUR 0.9 million.

The strongest growth was in the Environmental Services segment. Revenues with external customers increased by 19% to EUR 3.1 million. However, the first six months of 2012 contain cost restructuring. For this reason, EBIT shows a loss of EUR 0.6 million. In the next few quarters, the segment is not yet expected to make a positive contribution to earnings.

To read the full report please click here: http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/englisch/euz212e.pdf

Sales of approx. EUR 117 million and a result after tax and minority interests of approx. EUR 10 million are expected for the fiscal year 2012.

With around 600 employees the Eckert & Ziegler Group belongs to the largest providers of isotope components for radiotherapy and nuclear medicine worldwide.
If you have any questions please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@dont-want-spam.ezag.de, www.ezag.de